Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids


Kaléo, a privately held commercial-stage U.S. pharmaceutical company, today announced the execution of the first contract with the U.S. Department of Defense (DoD) for the procurement of the Rapid Opioid Countermeasure System (ROCS), a 10 mg Naloxone Auto-injector (naloxone hydrochloride injection) antidote for ultra-potent weaponized opioids. The contract includes an award for the manufacture and delivery of up to 788,000 units. “ROCS was developed to protect and maintain the readiness of the Joint Force and our NATO allies,” said Colonel Matthew Clark, PhD, PMP, the Joint Project Manager for CBRN Medical. “Weaponized synthetic opioids, such as fentanyl and carfentanyl, have been used operationally in the past and continue to pose a unique threat to our service members. This first delivery of ROCS auto-injectors is a great achievement.”

Read more about this news here.

Related articles

Recent articles